By Michael Erman (Reuters) -Bristol Myers Squibb posted much better-than-expected second-quarter results on Wednesday on ...

Bristol Myers Squibb posted much better-than-expected second-quarter results on Thursday on strong sales of its best-selling ...

Bristol-Myers Squibb offers strong cash flow, solid growth, and a high yield despite pricing pressure and pipeline risks.

The joint venture is launching a direct-to-consumer service of Eliquis after discussions with the Trump administration.

Bristol Myers Squibb & Co (NYSE:BMY) reported second-quarter 2025 revenues of $12.27 billion, beating the consensus of $11.31 ...

Bristol Myers Squibb and Pfizer will begin offering their top-selling heart medicine Eliquis through a new online service at a discounted price — the latest example of pharmaceutical companies ...

Bristol Myers Squibb and Pfizer on Thursday said they will start selling their blockbuster blood thinner, Eliquis, directly to patients at a more than 40% discount. Stream NBC 5 for free, 24/7 ...

Bristol Myers Squibb, Pfizer announce discounted direct-to-patient Eliquis The reduced rate will still be almost 10 times the average monthly out-of-pocket costs paid by commercially insured patients.

Bristol Myers and Pfizer will sell Eliquis directly to U.S. patients at a discounted rate with transparent pricing and nationwide delivery.

Bristol-Myers Squibb and Pfizer announce a 43% discount on Eliquis for uninsured U.S. patients, challenging traditional drug pricing models. Image (c) ConsumerAffairs ...

Bristol Myers and Pfizer said on Thursday they will start selling their blockbuster blood thinner, Eliquis, directly to cash-paying U.S. patients at a discount to its listed price as drugmakers ...